South Africa has cautiously welcomed the pledge of five pharmaceutical firms (GlaxoWellcome, Boehringer Ingelheim, Bristol-Myers Squibb, Roche, and Merck) to cut the prices of their HIV/AIDS drugs by up to 90% for African countries and other developing nations. Africa's AIDS activists are concerned that the deal will be conditional on governments undertaking not to promote the use of generic substances. In this regard South Africa¿s health minister, Mantho Tshabalala-Msimang, welcomed the decision by US President Bill Clinton to drop the threat of trade sanctions against countries planning to produce cheap generic drugs. In another development, South African Airways admitted that it had acted ¿unjustifiably¿ by excluding a job seeker who was HIV-positive. The airline agreed to pay the man R100,000 and his legal costs.